Editor's key points † The hypothalamic-pituitaryadrenal (HPA) axis plays an important role in critical illness. † Levels of cortisol during health and illness are highly dynamic. † There are gaps in our understanding of secretary patterns and control of cortisol during illness. † These gaps limit our ability to design optimal therapeutic regimens.
The HPA axis is a neuro-endocrine system that regulates circulating levels of glucocorticoid. Endogenous glucocorticoids are essential for normal homeostasis and play a pivotal role in the response to stress. Exogenous glucocorticoid use in major surgery and critical care is still controversial and identification of those who are relatively 'deficient' (if they exist at all) has so far not been possible. Changes in our understanding of the HPA axis, such as its highly dynamic pattern of secretion, the role of cortisol binding globulin (CBG) in regulating tissue levels of cortisol, the presence of extracellular receptors and altered genomic and non-genomic signalling render much of the previous clinical work obsolete, while at the same time open up new therapeutic avenues. We look at these recent insights and review in this context the evidence surrounding steroid use in critical illness and major surgery.
HPA control in health
The basic tenets of the HPA axis are relatively well known. The paraventricular nucleus (PVN) of the hypothalamus is the key regulator of HPA activity. In response to a stressor, the PVN releases corticotrophin-releasing hormone (CRH) and arginine vasopressin (AVP) into the hypothalamic-pituitary portal circulation. This then stimulates release of adrenocorticotropic hormone (ACTH) from the pituitary, which in turn increases both the rate of synthesis and secretion of cortisol from the zona fasciculata of the adrenal cortex. Circulating cortisol exerts a negative feedback effect at both the level of the pituitary to reduce ACTH secretion and in the hypothalamus to inhibit CRH release. Higher centres in the CNS (both limbic and brain stem pathways) project to the PVN to provide input from cognitive and physical stressors, while input from another hypothalamic nucleus-the suprachiasmatic nucleus (SCN) provides circadian information. An overview of the inputs and control to the HPA are outlined in Figure 1 . The input from the SCN provides the HPA axis with a unique pattern of activity; a circadian rhythm. This is low during periods of sleep and increases in anticipation of wakening to a peak in the morning. The circadian rhythm is actually made up of an ultradian rhythm of discreet pulses 1 (see night-time nadir reflects little or no pulsatile activity. These pulses result in rapidly changing levels of cortisol in both blood and the tissues 2 and exposure of cells to constant or pulsatile cortisol yields different transcriptional responses, even when the total cortisol exposure is the same.
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Although it had previously been assumed that there was a hypothalamic pulse generator, recent work using mathematical modelling has shown that pulsatility is inherent within the pituitary-adrenal system. 6 At a simple level, ACTH and cortisol can be imagined to be two balls in a 'Newton's cradle' system; one ball hits the other and causes movement, while coming to a stop itself and so the cycle continues. In the same way, ACTH stimulates cortisol production, cortisol levels increase and inhibit ACTH, decreasing levels of ACTH reduce the stimulus to cortisol; and the levels decrease. Thus there is a constant cyclical pattern of both ACTH and cortisol. The true picture is slightly more complex than this, with pulsatility only occurring in a 'goldilocks' area of moderate to high CRH drive and moderate to high delay in adrenal cortisol production. 6 The greater the adrenal delay, the greater the period of each pulse wave. In addition to hormonal control of the adrenals, there is also extensive innervation, both from sympathetic and sensory nerves. Both of these are carried in the splanchnic nerves. 7 Sympathetic innervation is from both cholinergic pre-ganglionic fibres and catecholaminergic postganglionic fibres. The nervous supply to the adrenals appears to sensitize them to ACTH, such that they elicit a larger cortisol 
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Fig 1 Basic HPA axis control. CNS, central nervous system; PVN, paraventricular nucleus; SCN, suprachiasmatic nucleus; CRH, corticotrophinreleasing hormone; ACTH, adrenocorticotrophic hormone. The hypothalamic PVN receives circadian inputs from the SCN and homeostatic and stress inputs from the brain stem and limbic areas. The PVN projects to the median eminence, where it releases CRH into the portal circulation. The CRH passes to the corticotroph cells of the anterior pituitary to release ACTH from preformed granules directly into the venous circulation. ACTH travels to the adrenals, where it activates both synthesis and release of cortisol. Cortisol exerts a negative feedback to both CRH at the hypothalamus and ACTH at the anterior pituitary. Increased firing by the splanchnic nerves sensitize the adrenals to ACTH; increasing cortisol synthesis and release.
response to the same level of ACTH. 8 9 It may also be that splanchnic neural inputs have a smaller role in the diurnal output of the adrenals.
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Cortisol binding globulin CBG has a major influence on tissue levels of cortisol and acts as both a reservoir and regulator of cortisol. Cortisol is a steroid hormone and is therefore relatively insoluble in plasma and must be carried by other molecules. Approximately 95% of plasma cortisol is bound to proteins; of which 80-90% is bound to CBG and 10-15% to albumin.
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The remaining 5% is unbound and, therefore, free to cross cell membranes and bind to glucocorticoid and mineralocorticoid receptors. The affinity of CBG for synthetic corticosteroids is negligible apart from prednisolone, which has an affinity about 50% of that of cortisol. 12 13 CBG is a 50 -60 kDa protein of the serpin (serine proteinase inhibitor) family which is secreted mainly from hepatocytes, but also the lung, kidney, and testes.
14 Its main function is to transport cortisol, although the extra-hepatic sites of production may have a role in locally regulating cortisol levels. Each CBG molecule binds one cortisol molecule 12 13 and this binding and release occurs by an allosteric method, common to all serpins. This involves a 'flip-flop' movement of the reactive loop (binding site) in and out of the body of the molecule. 15 16 This binding is saturable and CBG has a finite binding capacity, which occurs at plasma cortisol levels of 400-500 nmol litre 21 . 17 This means that at cortisol levels that exceed this, the free and therefore biologically active fraction of cortisol is massively increased. This is important in the context of cortisol pulsatility in that large pulses of cortisol will have their effects exaggerated by exceeding CBG binding capacity.
Serum CBG levels fluctuate slightly in a diurnal manner. The diurnal rhythm of CBG is in opposition to that of cortisol, therefore accentuating the changes in free (and therefore biologically active) cortisol throughout the day. 11 18 19 CBG's affinity for cortisol is altered by both temperature 20 21 and the activity of neutrophils. 22 These act to enhance cortisol delivery at areas of inflammation. At higher temperatures, the affinity of CBG for cortisol decreases, with a resultant increase in the free fraction. This increase is much more pronounced at lower levels of cortisol when CBG is not saturated and there is not already a relative excess of free cortisol. Activated neutrophils release elastase, which cleaves CBG resulting in the irreversible destruction of the cortisol binding site. Local free cortisol levels will therefore increase significantly at areas of neutrophil activation. Although changes in pH affect the binding of cortisol to albumin, they do not affect the cortisol -CBG interaction. 21 
Signal transduction
Glucocorticoids are fat-soluble and can therefore readily traverse the phospholipid bilayer of the cell wall. Figure 3 summarizes the process of glucocorticoid signal transduction.
The GR-ligand complex was previously thought to be stably bound to chromatin. 24 However, it is now thought that these interactions are much more dynamic. The GR-ligand complex interacts transiently with responsive ) and p23 hold GR in a conformation that allows cortisol binding. When cortisol is bound, these two proteins dissociate and are recycled. The CORT-GR complex dimerizes and is transported into the nucleus via the nuclear pore complex. This process is achieved by importins, which bind the activated-GR and shuttle it through the nuclear pore. When in the nucleus, activated-GR binds to glucocorticoid response elements (GRE) on the DNA to activate or repress transcription. mGR exists on some cells and exerts its effects via a non-genomic mechanism.
elements at the regulatory site and recruits a secondary set of factors, which then form a complex 25 26 to interact with chromatin and promote transcription. This process is not the unidirectional, ordered process that was once thought, but a rapid cycling of both GR 27 and transcription factors 28 on and off the chromatin, with each chromatin interaction lasting around 10 -20 s. 27 29 The interaction of the ultradian rhythm with receptor binding is important for physiological functioning. Real-time, live cell imaging has shown that transcription of GR responsive genes occurs in pulses that tracks the pulses of natural GR ligand 4 (corticosterone in the rat, cortisol in the human). The equilibrium of the GR-ligand complex interaction with DNA allows GR to bind cyclically with DNA. At the peak of each pulse the GR-ligand complex binds to promoter sequences of glucocorticoid responsive genes and then rapidly cycles off the chromatin. It is this rapid cycling that allows HPA output (i.e. gene transcription) to respond quickly to stressors. 30 During the 'off' phase of the cycling, the complex comes off the GRE and as the ligand levels decrease in the trough of a pulse, there is an increased likelihood of dissociation of cortisol from the GR. Although unliganded GR can remain in the nucleus, it is unable to bind to DNA. It can however, regenerate into hormone responsive complexes with hsp90 31 32 ready to rapidly respond to the next pulse.
Therefore, the trough of each pulse is critical to allow regeneration of the GR-complex so that cortisol may bind again and exert its transcriptional effect. GR can positively and negatively regulate transcription 33 34 and the gene response to glucocorticoid is diverse, 33 34 with some genes induced transiently, continuously, or to a plateau response. Some effects of glucocorticoids are too rapid to be a result of transcription, with effects seen in seconds or minutes. This led to the discovery that GR can also exist in a membrane associated state, particularly on neuronal, 35 immune, 36 and vascular cells. 37 38 In neuronal cells, the effects of membrane associated GR (mGR) are widespread depending on the area of the brain, but can affect ion channels, receptors and downstream signalling. 35 In the immune system, inhibition of T-cells by dexamethasone occurs within 10 min in a GR dependent manner 36 and this is dynamic, with the number of membrane-GR positive lymphocytes increasing with increasing activation of the immune system and autoimmune disease severity. 39 Physiological doses of hydrocortisone have also been shown to rapidly activate endothelial nitric oxide synthase (eNOS) in neuro-vascular tissue by nongenomic mechanisms. 37 38 Epigenetics Epigenetics refers to changes in the genome, which occur without modifying the DNA sequence. Although previously thought to be long term and heritable, it is emerging that these modifications can be short term and highly dynamic. In this way, genes can be activated or repressed and a genetic output based on previous experience can be generated.
It has long been known that the HPA axis can be programmed by early life events 40 and that previously encountered stress, such as maternal separation, 41 child abuse, 42 or exposure to endotoxin 43 alters the way in which the HPA responds to stressors encountered later in life. Exposure to early life stress appears to sensitize the HPA, such that an exaggerated 40 41 43 and more rapid 43 stress response is seen in later life. Epigenetic mechanisms are thought to account for this, particularly DNA methylation of the GR promoter region. 44 There is, however, no work on the influence of epigenetics on the cortisol response and outcome of major surgery and critical care in humans.
Adrenal control in chronic disease
Altered patterns of glucocorticoid secretion occur in chronic disease states including major depression, 45 obstructive sleep apnoea, 46 and immune mediated arthritides. 47 Although patients with inflammatory conditions are often treated with exogenous steroids, pathophysiological levels of glucocorticoid play an important role in modulating inflammation. At a basic level, this can be seen with the inflammatory arthritides, where 'morning stiffness' follows the period of overnight low cortisol 47 and in experimental models, adrenalectomized rats show an increase in the disease severity of induced arthritis. 48 49 The changes in secretory patterns of cortisol seen during chronic illness are that the pulses of cortisol in the ultradian rhythm increase in amplitude and the adrenal glands continue to pulse during the night-time nadir phase. 46 This leads to the well recognized features of an overall increased cortisol levels with 'blunting' of the diurnal rhythm. In obstructive sleep apnoea, these patterns return to normal after a period of treatment with night-time continuous positive airway pressure (CPAP). 46 Inflammation and inflammatory mediators drive the increased production of the anti-inflammatory glucocorticoids, and despite the activity of the classical negative feedback loop 50 the cytokine induced activation of the HPA overcomes this. However, long-term exposure to these increased levels of glucocorticoid can result in resistance. 51 About one-third of patients fail to respond to exogenous steroids in inflammatory diseases and leukaemias. 52 Glucocorticoid resistance can occur because of abnormalities in the GR itself 53 or nuclear importing machinery 54 55 and may be inherited or induced. Inherited glucocorticoid resistance often leads to raised circulating levels of cortisol, but without the stigmata of Cushing's disease. 53 Induced glucocorticoid resistance has been most extensively studied in chronic diseases such as asthma, 56 57 rheumatoid arthritis 52 and inflammatory bowel disease. 55 These inducible changes are attributable to downregulation of GR numbers in those with raised glucocorticoids 51 54 58 and changes induced by the pro-inflammatory cytokines of the disease process itself. The clinical effects of these changes in critical illness has still not been established. However, induced changes are beginning to be elucidated in sepsis and critical illness via similar mechanisms to those in chronic disease. 59 Teasing out which patients may need increased doses of steroid to overcome resistance and even whether this is useful at all is still to be established. Endogenous glucocorticoid secretion may be reduced either as a result of feedback from exogenous glucocorticoid therapy or as a result of primary adrenal, pituitary or hypothalamic disease. Studies in patients on adrenal hormone replacement therapy have revealed how important the secretory pattern of glucocorticoids is for health. Not only do patients who are on 'optimal' replacement glucocorticoids complain of weariness, fatigue and stress intolerance, 60 but patients with Addison's disease who are receiving cortisol replacement have double the mortality of the general population of the same age-group. 61 It is clear that these patients on non-pulsatile hormone replacement will have abnormal regulation of GR responsive genes, including those in the immune system. The drive towards less frequent dosing of medicines is not appropriate for glucocorticoids and this is leading to the development of novel drug delivery systems that recreate normal ultradian rhythms.
Adrenal control in major surgery and critical illness
Major surgery and critical illness are both significant challenges to homeostasis. They both activate compensatory autonomic and neuro-endocrine systems, of which a pivotal one is the HPA axis. Total levels of cortisol increase, 62 -64 as does CBG, 21 although tissue levels of free cortisol are difficult to calculate as CBG saturation, 17 increase in body temperature, 21 acidosis, 21 and neutrophil activity 22 all act to increase the free fraction of cortisol. It is likely that this may result in differential levels of free cortisol in different tissues. Initially, production of the pro-inflammatory cytokines; tumour necrosis factor a (TNF-a) and interleukins-1 (IL-1) and IL-6 65 cause direct stimulation of CRH and ACTH from the hypothalamus and pituitary respectively. This drives an overall increase in plasma cortisol levels. While plasma levels of cortisol remain persistently elevated after major surgery, by the first postoperative day, ACTH has returned to normal or below preoperative levels. 63 64 This implies that the mechanisms controlling cortisol output from the adrenal are different, or are at least sensitized differently in those with acute systemic inflammation. It is possible that some of the increased adrenal sensitivity comes from increased splanchnic nerve firing 8 9 and in response to inflammatory mediators. The inflammatory mediators TNF-a, IL-1 and IL-6 have disparate effects on adrenal production of cortisol. TNF-a and IL-6 work directly via receptor mediated mechanisms, 66 while
IL-1 appears to mediate its effects indirectly by local release of prostaglandins. 67 Although not fully elucidated, it appears that TNF-a has both inhibitory 68 and stimulatory 66 69 effects on the adrenal production of cortisol. Overall, it has been shown that at low concentrations of TNF-a the inhibitory effects dominate and at higher concentrations the stimulatory effects dominate. 66 However, much of this work is in adrenal cell culture and not in vivo. IL-6 has been well studied and has universally been found to increase cortisol secretion in a dose dependent manner, 70 71 with a high density of receptors in both the zona fasciulata and pituitary. 72 It is somewhat slow to exert this effect on the adrenals; requiring between 12-24 h of stimulation for zona fasciculata cells to produce more cortisol. 71 73 IL-1 has been less well studied, but again, also appears to increase cortisol production. 71 Stimulation with stressors at different phases during the ultradian pulse cycle results in different outcomes. Animal models that were stressed during the rising phase of a pulse showed an exaggerated glucocorticoid response compared with their response during the decreasing phase of a pulse 74 -an effective refractory period. The mechanisms controlling this are unclear but computational modelling suggests that it is the coupling between the stress induced hypothalamic input and the rhythmicity of pituitary-adrenal network that governs the response to a stressor. 75 The impact of acute stressors such as surgery during different phases of the pulse cycle in humans has not been studied. Both characterizing and elucidating the control and impact of ultradian rhythms in this situation is the subject of ongoing work.
HPA control in those taking exogenous steroids
It is relatively well known that patients on corticosteroids have a reduced basal secretion of cortisol and a reduced response to stress as a result of negative feedback. Normal ultradian pulsatility is blunted by even small doses of exogenous steroid, such as that found in skin treatment creams. Patients having major surgery who are taking supplementary steroids have traditionally been given increased doses during the perioperative period to cover the 'stress' response. A number of studies have shown that in terms of haemodynamic and mortality outcomes, this is probably not required 76 -78 (this does not apply to those on physiological replacement for Addison's disease, who are unable to produce any cortisol). Converting patients' regular steroids to an i.v. equivalent if they are unable to take medication by mouth is all that is needed, even for major surgery. This is in contrast with what happens in critical illness, where supplementary hydrocortisone appears to improve haemodynamic, but not mortality outcomes (see Table 1 ). This highlights the gap in our understanding between the physiology of the HPA under 'stress' and what happens in clinical randomized controlled trials. All studies used patients taking ,15 mg day 21 prednisolone (or equivalent) and many had abnormal responses to synthetic ACTH. Until we characterize 'normal' responses, we do not know if it is the combination of supplementary steroids and endogenous production that meets the patient's need, or if it is the exogenous steroids alone. Stopping or reducing a patient's steroids abruptly in BJA or near the perioperative period is associated with hypotension and haemodynamic compromise. 76 Therapeutic use of glucocorticoids in major surgery and critical care
The use of glucocorticoids in major surgery and critical illness is still controversial. The research can be framed into two questions: first, is there a group of patients among the critically ill who are in a state of relative adrenal insufficiency (and how is this diagnosed) and secondly, do therapeutic glucocorticoids improve outcome in major surgery and critical illness? Sub-optimal adrenal function has been recognized as a cause of circulatory failure since 1911, 79 and interest in testing for relative adrenal insufficiency (now termed Critical Illness Related Corticosteroid Insufficiency-CRCI 80 ) in the context of septic shock since the 1950s. 81 82 Despite multiple attempts to identify who these patients are using point measurements and changes in cortisol 83 and free, 83 -85 synthetic ACTH tests, 83 -86 eosinophil counts, 83 urinary, 87 and salivary cortisol, 88 none have been shown to be functionally useful at detecting this subset of the population. 80 Ultradian pulsing of cortisol shows that cortisol can vary in the same patient by up to 600 nmol litre 21 within an hour. 89 Therefore, any test that uses a small number of cortisol measurements is likely to be unhelpful in diagnosis.
Therapeutic glucocorticoids in sepsis and critical care
The question of whether glucocorticoids in major surgery and critical illness are useful is separate to that of those who are 'relatively deficient'. Despite consensus statements 80 and large-scale reviews, 90 -92 there is no robust evidence that glucocorticoids reduce mortality or other measures of outcome in the critical care unit, although there is a trend towards a shorter duration of vasopressor use and ventilator times. These reviews and meta-analyses all include disparate studies using different synthetic glucocorticoids, given at different doses, using both continuous infusions and boluses for differing time periods. This is important, as not all exogenous steroids have the same transcriptional or physiological effect 93 and in chronic disease, it appears to be both the amount and pattern of glucocorticoid that affect outcome. 61 Most recent studies have used hydrocortisone at 'low-dose' (,300 mg day 21 ). CORTICUS 94 is the largest of these (499 patients) and used 6 hourly bolus doses of 50 mg. CORTICUS showed no difference in terms of death, although shock was reversed more rapidly in those receiving hydrocortisone. It was however underpowered, with only 62% of the number of patients recruited required to achieve adequate power. As CORTICUS was published in 2008, we could find no new randomized controlled trials of corticosteroids alone vs placebo in sepsis.
Five randomized trials comparing low-dose hydrocortisone alone to placebo were published before 2008 (see Table 1 )-the sum total of patients in all of these other studies is significantly less than the number of patients in CORTICUS. Again, they are methodologically disparate, with some using bolus doses 95 96 and some using infusions. 97 -99 As we have seen previously, associating these in the same group may not be helpful, as different patterns of GR-ligand binding may lead to quantitatively and qualitatively different transcriptional outcomes. 30 -32 The one study comparing bolus doses to continuous infusions assessed outcome in terms of bloodglucose control, not mortality. 100 Other studies of so-called 'low-dose' corticosteroids in sepsis have included prednisolone 101 and dexamethasone. 102 The heterogenous nature of the dosing regimes and drugs associated with small sample sizes makes real conclusions from any study or meta-analysis fraught with uncertainty. Studies of high-dose (immunosuppressive) corticosteroids in sepsis halted in the late 1980s, when a number of studies showed that high-dose steroids effected little difference in outcome at the expense of higher rates of superinfection. 103 -105 106 -108 This was with the exception of Schumer and colleagues, 109 where there was a remarkably lower mortality in those receiving steroids (see Table 2 ).
The clinical bottom line is that evidence for the use of any corticosteroids in critical care is lacking, mainly because of disparate, underpowered trials and heterogenous meta-analyses. There is a consistent trend that using low-dose hydrocortisone improves physiological parameters (time on ventilator, time on vasopressors), although not mortality, without deleterious effects. However, as we still have no accurate model for 'normal' adrenal function and control in critical illness, it is likely that the optimal therapeutic regimen is still some way off.
Therapeutic glucocorticoids in cardiac surgery
Steroids theoretically offer benefits in cardiac surgery, as it is a large, sterile physiological insult. The effect of supplementary steroids in cardiac surgery is similar to other interventions that have attempted to reduce the inflammatory response; there is robust evidence for biochemical improvement, but this does not translate to a survival benefit. Evidence for the use of corticosteroids in cardiac surgery also suffers from many of the problems of their use in critical care; heterogeneity and small sample sizes using differing steroids and dose regimens. Small sample sizes are a particular problem when studying cardiac surgery; UK survival rates for cardiac surgery are .98% 110 and therefore large trials are required to achieve adequate power to detect even small changes in mortality.
The profile of clinical studies in cardiac surgery is also slightly different to that in sepsis, in that the vast majority of studies investigate the effects of methylprednisolone and dexamethasone. This may reflect investigators perceptions that improvements in outcome will come from suppressing the inflammatory response of cardiac surgery rather than treating a group of patients who are relatively deficient in endogenous corticosteroids or utilizing their permissive effects on vasculature as suggested by the use of low-dose hydrocortisone, the prevalent drug in recent sepsis trials. Three large meta-analyses have been published in the previous 5 years. 91 111 112 None of them could demonstrate a survival benefit. Two of them showed benefits with regard to morbidity (atrial fibrillation and length of stay), which was not offset by side-effects. 111 112 The Cochrane analysis, 91 which included somewhat more detailed statistics, showed a reduction in atrial fibrillation only, but at the expense of an increase in gastrointestinal bleeding. It is again difficult to discern a clinical conclusion from studies of steroid use in cardiac surgery in the face of available evidence. Huge, multicentre trials are required to demonstrate a survival benefit from supplementary steroids. However, smaller numbers would be needed to elucidate a clinically (and financially) important difference in critical care stay and vasopressor use if there were one. This is currently happening, with two randomized controlled trials; The Dexamethasone for Cardiac Surgery (DECS) Trial 113 (n¼4, 494) which has recently reported and the SIRS (Steroids In CaRdiac Surgery: http://www.clinicaltrials.gov: study number NCT00427388) which has a n¼7500 patients and has currently recruited around one-third of these. The DECS trial gave single bolus, high-dose (1 mg kg 21 ) dexamethasone to patients having cardiac surgery with cardiopulmonary bypass. It did not show any significant difference in a composite outcome of death, myocardial infarction, stroke, renal or respiratory failure within 30 days. There was a reduction in length of mechanical ventilation, intensive care unit, and hospital stays in the dexamethasone group, and postoperative infection and at the expense of higher glucose levels. The SIRS trial is using methylprednisolone and is still to finish recruiting. A focus switch from immunosuppression to augmentation of cardiovascular effects using low-dose hydrocortisone may also provide an important area of investigation.
Therapeutic glucocorticoids in major non-cardiac surgery
Glucocorticoids have wide-ranging effects and as such, form part of the therapeutic regimen for numerous other areas of surgery. The heterogenous nature of this area, in both the type of drugs and outcomes for which they are used make review of this subject well beyond the scope of this article. Although not immediately obvious, characterizing the HPA axis response in minor surgery may be important for our understanding of major surgery and critical illness. It provides a natural model of an acute insult without high concentrations of systemic inflammatory mediators and without marked changes in plasma proteins.
Future directions
The key to improving care is to understand the pathophysiology of the HPA axis in critical care and major surgery. We still have no truly detailed model of 'normal' adrenal functioning in these situations. Until we have done this, we cannot hope to move forward with diagnostic and therapeutic studies.
Simple questions that need answering are: does ultradian pulsatility persist in this context? Is the pattern of secretion important in terms of morbidity and mortality outcomes? If a 'normal' response is pulsatile what are the downstream effects and does this translate to fluctuating levels of free cortisol? Further downstream, what is the effect at a receptor and transcriptional level? Moving upstream, to what extent do ACTH, the splanchnic nerves and inflammatory mediators each drive the adrenal glands in critical illness (if at all)? Once we begin to answer these questions we can use that knowledge to design meaningful tests of HPA function in critical illness and begin to offer an optimal therapeutic regimen.
Conclusions
The HPA axis is a system that has multiple effects on almost all tissues of the body and plays a crucial role in regulating inflammation. Levels of cortisol fluctuate throughout the day in a diurnal rhythm, underlying which is an ultradian rhythm of approximately hourly pulses, which affects transcriptional outcomes. Pulsatility is not the result of a 'pulse generator', but is inherent within the system. These patterns of secretion change in both acute and chronic illness as a result of inflammatory mediators, splanchnic nerve output and central nervous system control. Levels of cortisol in both normal and illness states are highly dynamic and so static assessment tools for diagnosing corticosteroid related critical illness insufficiency not likely to be useful. Knowledge of 'normal' adrenal output in different states of critical illness and major surgery are likely to be required before the optimal dosing regimen is found.
